AbbVie Inc vs Carvana Co — how do they compare? AbbVie Inc trades at $249.53 (market cap $438.19B), while Carvana Co trades at $71.99 (market cap $81.54B). The key difference: AbbVie Inc is far larger — about 5.4× Carvana Co's market cap, and AbbVie Inc pays a 2.79% dividend while Carvana Co pays none. Which is the better fit depends on your goals.
| ABBV | CVNA | |
|---|---|---|
Market Cap | $438.19B | $81.54B |
Sector | Health | Consumer Cyclical |
52-Week High | $263.58 | $95.69 |
52-Week Low | $197.38 | $56.27 |
Enterprise Value | $502.45B | $84.03B |
Dividend Yield | 2.79% | — |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
Carvana (CVNA) trades at $70.85, up 3.73% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue surged 52% year-over-year in Q2 2026 to $7.38 billion, driven by record retail unit growth, though profit margins face pressure. The stock is near its consensus price target of $87.18, with analyst sentiment split between Buy and Hold ratings.
Outlook remains positive due to aggressive scaling and AI-driven cost efficiencies, but risks include high debt levels and competitive threats. Investors should weigh robust growth against valuation concerns, with the current P/E of 37.5 reflecting high expectations. Near-term performance hinges on execution of margin improvement goals.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →